دورية أكاديمية
أعرض في EDS

Effect of anticoagulants on fibrin clot structure: A comparison between vitamin K antagonists and factor Xa inhibitors.

التفاصيل البيبلوغرافية
العنوان: Effect of anticoagulants on fibrin clot structure: A comparison between vitamin K antagonists and factor Xa inhibitors.
المؤلفون: Gauer JS; Discovery and Translational Science Department Institute of Cardiovascular and Metabolic Medicine University of Leeds Leeds UK., Riva N; Department of Pathology Faculty of Medicine & Surgery University of Malta Msida Malta., Page EM; Discovery and Translational Science Department Institute of Cardiovascular and Metabolic Medicine University of Leeds Leeds UK., Philippou H; Discovery and Translational Science Department Institute of Cardiovascular and Metabolic Medicine University of Leeds Leeds UK., Makris M; Sheffield Haemophilia and Thrombosis Centre University of Sheffield Sheffield UK., Gatt A; Department of Pathology Faculty of Medicine & Surgery University of Malta Msida Malta., Ariëns RAS; Discovery and Translational Science Department Institute of Cardiovascular and Metabolic Medicine University of Leeds Leeds UK.
المصدر: Research and practice in thrombosis and haemostasis [Res Pract Thromb Haemost] 2020 Oct 25; Vol. 4 (8), pp. 1269-1281. Date of Electronic Publication: 2020 Oct 25 (Print Publication: 2020).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 101703775 Publication Model: eCollection Cited Medium: Internet ISSN: 2475-0379 (Electronic) Linking ISSN: 24750379 NLM ISO Abbreviation: Res Pract Thromb Haemost Subsets: PubMed not MEDLINE
أسماء مطبوعة: Publication: 2023- : [New York] : Elsevier
Original Publication: Hoboken, NJ : John Wiley & Sons, Inc., [2017]-
مستخلص: Background: Abnormal clot structure has been identified in patients with thrombotic disorders. Anticoagulant therapy offers clear benefits for thrombosis prevention and treatment by reducing blood clot formation and size; nevertheless, there are limited data on the effects of different anticoagulants, where clotting is initiated with different triggers, on clot structure.
Objectives: Our aim was to investigate the effects of vitamin K antagonists and factor Xa inhibitors on clot structure.
Methods: Clots from pooled plasma spiked with rivaroxaban, apixaban, or enoxaparin, as well as plasma from patients on warfarin, were compared to plasma without anticoagulation. The kinetic profile of polymerizing clots was obtained by turbidity, fiber density was determined by confocal microscopy, clot pore size was investigated by permeation, and fiber size was analyzed using scanning electron microscopy. Clotting agonist was either tissue factor or thrombin.
Results: Following clotting with tissue factor, all anticoagulated clots had a significantly increased lag time, with the exception of enoxaparin. Rivaroxaban additionally led to significantly less dense and more permeable clots, with thicker fibers. In contrast, turbidity analysis following initiation with thrombin showed few effects of anticoagulation, with only enoxaparin leading to a prolonged lag time. Enoxaparin clots made with thrombin were less dense and more permeable.
Conclusion: Our results show that anticoagulants modulate clot structure particularly when induced by tissue factor, most likely due to reduction of thrombin generation. We propose that the effects of different anticoagulants could be assessed with a global clot structure measurement such as permeation or turbidity, providing information on clot phenotype.
(© 2020 The Authors. Research and Practice in Thrombosis and Haemostasis published by Wiley Periodicals LLC on behalf of International Society on Thrombosis and Haemostasis (ISTH).)
References: J Am Coll Cardiol. 2017 Jul 4;70(1):1-25. (PMID: 28527533)
Blood. 2003 Apr 15;101(8):3008-13. (PMID: 12506014)
Circulation. 2019 Mar 5;139(10):e56-e528. (PMID: 30700139)
Circ Res. 2016 Apr 29;118(9):1340-7. (PMID: 27126645)
Thromb Haemost. 2015 Apr;113(4):851-61. (PMID: 25518887)
Blood Coagul Fibrinolysis. 2003 Sep;14(6):557-62. (PMID: 12960609)
J Thromb Haemost. 2003 Mar;1(3):551-8. (PMID: 12871465)
Arterioscler Thromb Vasc Biol. 2016 Apr;36(4):692-9. (PMID: 26848157)
Arterioscler Thromb Vasc Biol. 2012 Jun;32(6):1466-76. (PMID: 22516070)
Blood. 2009 Nov 5;114(19):4272-8. (PMID: 19690336)
Ther Clin Risk Manag. 2015 Jun 24;11:967-77. (PMID: 26150723)
Thromb Res. 2010 Mar;125(3):220-3. (PMID: 19272635)
Pol Arch Intern Med. 2019 Jun 28;129(6):377-385. (PMID: 31063157)
J Thromb Haemost. 2005 Feb;3(2):321-31. (PMID: 15670039)
Arterioscler Thromb Vasc Biol. 2001 Jul;21(7):1094-6. (PMID: 11451734)
J Thromb Haemost. 2013 Feb;11(2):315-24. (PMID: 23256818)
J Thromb Haemost. 2014 Oct;12(10):1580-90. (PMID: 25302663)
J Clin Invest. 2018 Aug 1;128(8):3356-3368. (PMID: 29723163)
Circulation. 2002 Oct 8;106(15):1938-42. (PMID: 12370216)
Res Pract Thromb Haemost. 2018 Jul 17;2(4):696-707. (PMID: 30349889)
Ann Med. 2011 Mar;43(2):116-23. (PMID: 21254900)
Br J Haematol. 2011 Mar;152(6):758-65. (PMID: 21250974)
Drug Saf. 1991 Jan-Feb;6(1):54-69. (PMID: 2029354)
J Thromb Haemost. 2012 Oct;10(10):2179-81. (PMID: 23193585)
Thromb Res. 2016 Jan;137:85-91. (PMID: 26589270)
J Thromb Haemost. 2019 Apr;17(4):618-626. (PMID: 30725502)
J Physiol Pharmacol. 2018 Aug;69(4):. (PMID: 30415236)
Nat Rev Cardiol. 2011 Jul 05;8(9):502-12. (PMID: 21727917)
Res Pract Thromb Haemost. 2020 Oct 25;4(8):1269-1281. (PMID: 33313466)
Lancet. 2000 May 6;355(9215):1627-32. (PMID: 10821379)
J Thromb Thrombolysis. 2016 Nov;42(4):535-44. (PMID: 27554264)
Thromb Haemost. 2010 May;103(5):1076-84. (PMID: 20216982)
Thromb Res. 2016 Jan;137:189-195. (PMID: 26577257)
J Thromb Haemost. 2010 Apr;8(4):790-8. (PMID: 20088944)
Clin Exp Med. 2018 Aug;18(3):325-336. (PMID: 29417256)
Arterioscler Thromb Vasc Biol. 2008 Dec;28(12):2247-54. (PMID: 18974382)
Transfus Apher Sci. 2008 Feb;38(1):15-23. (PMID: 18282807)
Blood. 2009 Nov 26;114(23):4886-96. (PMID: 19797520)
Clin Med (Lond). 2017 Jun;17(3):233-244. (PMID: 28572224)
معلومات مُعتمدة: United Kingdom WT_ Wellcome Trust; RG/13/3/30104 United Kingdom BHF_ British Heart Foundation
فهرسة مساهمة: Keywords: LMWH; anticoagulants; factor Xa inhibitors; fibrin clot; warfarin
تواريخ الأحداث: Date Created: 20201214 Latest Revision: 20240331
رمز التحديث: 20240331
مُعرف محوري في PubMed: PMC7695561
DOI: 10.1002/rth2.12443
PMID: 33313466
قاعدة البيانات: MEDLINE
الوصف
تدمد:2475-0379
DOI:10.1002/rth2.12443